Cannabis
The cannabis industry is entering a new federal era. In April 2026, the Department of Justice rescheduled state-licensed medical marijuana and FDA-approved cannabis products from Schedule I to Schedule III, the most significant federal cannabis policy action in more than 50 years. Broader rescheduling remains under review.
The US cannabis industry was estimated at $34 billion in 2025, according to Whitney Economics, and the post-rescheduling environment is expected to accelerate growth — particularly in the regulated medical market, where Section 280E no longer applies to qualifying operators. International markets, including Canada, continue to mature, and EisnerAmper supports cannabis organizations and their investors across both.
Cannabis remains federally regulated, but the framework has shifted materially. Schedule III status changes the tax position for many operators, the Drug Enforcement Administration (DEA) continues to evaluate broader rescheduling, and the November 2026 redefinition of hemp under federal law will reshape the regulatory picture for businesses. New and established cannabis organizations need accounting and advisory support built around this complexity.
How EisnerAmper Supports Cannabis Organizations
EisnerAmper brings real-world industry experience across the full cannabis supply chain, including cultivators and processors, dispensaries, ancillary providers, and investors. Our team works alongside operators to anticipate and address what comes next.
For cannabis organizations, including plant-touching operators where service is permitted and the ancillary organizations that support them, EisnerAmper provides a full range of accounting, tax, advisory, and outsourcing services. Our scope covers the full lifecycle, from formation through growth, transactions, and exit. As your organization evolves, our team is built to evolve with it.
Proactive Insight on Regulatory Changes
Compliance Support
Direct Partner Access
What's on Your Mind?
Gregory Chin
Gregory Chin is a Partner in the firm’s Transaction Advisory practice with 30 years of experience advising clients on buy-side and sell-side financial diligence.
Start a conversation with Gregory
Cannabis Insights
EisnerAmper supports operators and investors as federal policy shifts, from Schedule III rescheduling and IRC Section 280E to multi-state compliance and the evolving federal landscape. Explore cannabis insights and how we provide accounting, tax, advisory, and outsourcing services across the full supply chain.
